PMCB · NASDAQ
PharmaCyte Biotech (PMCB) Stock Price & Fundamentals
PharmaCyte Biotech (PMCB) closed at $546.87 on Oct 9, 2026, up 0.16% from the previous close of $546.00.
Share price, past year
1Y +35.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $546.87 |
| Sep 30, 2026 | $522.25 |
| Aug 31, 2026 | $522.73 |
| Jul 31, 2026 | $511.22 |
| Jun 30, 2026 | $541.93 |
| May 29, 2026 | $554.27 |
| Apr 30, 2026 | $531.81 |
| Mar 31, 2026 | $518.36 |
| Feb 27, 2026 | $500.38 |
| Jan 30, 2026 | $477.76 |
| Dec 31, 2025 | $441.41 |
| Nov 28, 2025 | $425.37 |
| Oct 31, 2025 | $429.38 |
Key statistics
- Market cap
- $5.87B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$16.15M
- Shares outstanding
- 10.7M
- Dividend yield
- —
- 52-week range
- $403.86 – $562.79
PharmaCyte Biotech's market cap is $5.87B, based on a share price of $546.87 and 10.7M shares outstanding as of Jul 31, 2026.
Financials
PharmaCyte Biotech reported revenue of $0.00 for fiscal 2026.
PharmaCyte Biotech reported a net loss of $19.42M in fiscal 2026.
PharmaCyte Biotech's fiscal 2026 net loss was its first in at least 3 years.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended Apr 30, 2026 | $0.00 | — | −$19.42M | — | −$2.77 | — |
| FY2025ended Apr 30, 2025 | $0.00 | — | $30.66M | — | $3.19 | — |
| FY2024ended Apr 30, 2024 | $0.00 | — | $333.76K | — | −$1.80 | — |
| FY2023ended Apr 30, 2023 | $0.00 | — | −$4.32M | — | −$0.22 | — |
| FY2022ended Apr 30, 2022 | $0.00 | — | −$4.24M | — | −$0.27 | — |
| FY2021ended Apr 30, 2021 | $0.00 | — | −$3.55M | — | −$2.45 | — |
| FY2020ended Apr 30, 2020 | $0.00 | — | −$3.83M | — | — | — |
| FY2019ended Apr 30, 2019 | $0.00 | — | −$4.07M | — | — | — |
| FY2018ended Apr 30, 2018 | $0.00 | — | −$6.83M | — | — | — |
| FY2017ended Apr 30, 2017 | $0.00 | — | −$4.44M | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2027ended Jul 31, 2026 | $0.00 | −$5.08M | −$0.54 |
| Q4 FY2026ended Apr 30, 2026 | $0.00 | −$4.39M | — |
| Q3 FY2026ended Jan 31, 2026 | $0.00 | $746.86K | −$0.17 |
| Q2 FY2026ended Oct 31, 2025 | $0.00 | −$7.42M | −$1.24 |
| Q1 FY2026ended Jul 31, 2025 | $0.00 | −$8.36M | −$1.23 |
| Q4 FY2025ended Apr 30, 2025 | $0.00 | $11.75M | — |
| Q3 FY2025ended Jan 31, 2025 | $0.00 | −$3.05M | −$0.44 |
| Q2 FY2025ended Oct 31, 2024 | $0.00 | −$1.47M | −$0.39 |
Company profile
- Name
- PharmaCyte Biotech, Inc.
- Ticker
- PMCB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169
- Incorporated in
- NV
- Fiscal year ends
- April
- SEC CIK
- 0001157075
Recent SEC filings
- Sep 14, 2026
- Jul 29, 2026
- Apr 2, 2026
- Mar 17, 2026
- Dec 18, 2025
- Dec 5, 2025
- Oct 31, 2025
- Sep 15, 2025
Frequently asked questions
What is PharmaCyte Biotech's stock price?
PharmaCyte Biotech (PMCB) closed at $546.87 on Oct 9, 2026, up 0.16% from the previous close of $546.00.
What is PharmaCyte Biotech's market cap?
PharmaCyte Biotech's market cap is $5.87B, based on a share price of $546.87 and 10.7M shares outstanding as of Jul 31, 2026.
How much revenue does PharmaCyte Biotech make?
PharmaCyte Biotech reported revenue of $0.00 for fiscal 2026.
Does PharmaCyte Biotech pay a dividend?
PharmaCyte Biotech's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from PharmaCyte Biotech, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures